Humanized and chimeric monoclonal antibodies to CD81
Humanized or chimeric anti-CD81 (cluster of differentiation 81) monoclonal antibodies are provided. The antibodies bind to human CD81, and find use in various therapeutic methods, including without limitation the reduction or prevention of tumor metastasis. Further provided are heavy chain and light chain variable region sequences as well as associated complementarity-determining region (CDR) sequences.
1. An isolated chimeric or humanized antibody that specifically binds to human CD81, and comprises a variable heavy region with CDR1, CDR2 and CDR3 from SEQ ID NO:1, and a variable light region with CRD1, CDR2 and CDR3 from SEQ ID NO:4.
2. The antibody of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:1, 2 or 3.
3. The antibody of claim 2 , wherein the variable heavy region further comprises a human Fc.
4. The antibody of claim 3 , wherein the human Fc is an IgG.
5. The antibody of claim 4 , wherein the IgG provides for high ADCC activity.
6. The antibody of claim 3 , wherein the Fc region engineered for enhanced ADCC activity.
7. The antibody of claim 6 , wherein the Fc region comprises glyco-engineered carbohydrate side chains.
8. The antibody of claim 6 , wherein the Fc region comprises amino acid substitutions that enhance binding to FcγRIIIA.
9. The antibody of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:4, 5 or 6.
10. The antibody of claim 1 , further comprising amino terminal amino acid residues linked by cleavable linkers.
11. A method of reducing breast cancer or lymphoma metastasis in a human subject in need thereof, the method comprising the step of administering to a subject a therapeutically effective amount of an isolated chimeric or humanized antibody that specifically birds to human CD81, and comprises a variable heavy region with CDR1, CDR2 and CDR3 from SEQ ID NO:1, and a variable light region with CDR1, CDR2 and CDR3 from SEQ ID NO;4.